Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zalcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.62 |
| ▸ | ALB | P02768 | 3/20 | 0.62 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.62 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.62 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | POLG | P54098 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zalcitabine SCHEMBL21100417 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL598496 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3715526 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL9194365 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3598 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL12149465 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL8094882 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3235525 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL27555151 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL29277683 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| WO-1990001036-A1 | NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1990-02-08 | — | — | WO | disclosed |
| EP-0352248-A1 | Nucleoside derivatives | Medivir Aktiebolag (SE) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | LMNA 4838/4885PDE3A 3343/4885ALB 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.